|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
Q1 FY2021
As of Mar 31, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||||||
| Cash and due from banks | |||||||||||||||||||
| Federal funds sold | |||||||||||||||||||
| Interest earning deposits with banks | |||||||||||||||||||
| Cash and cash equivalents | |||||||||||||||||||
| Debt securities available-for-sale, at fair value | |||||||||||||||||||
| Equity securities, at fair value | |||||||||||||||||||
| Restricted stocks, at cost | |||||||||||||||||||
| Loans receivable, net of allowance for credit losses of $4,509 at September 30, 2025 and $4,356 at December 31, 2024 | |||||||||||||||||||
| Loans receivable, net of allowance for credit losses of $3,992 at December 31, 2022, Prior to adoption of ASC 326 | |||||||||||||||||||
| Premises and equipment, net | |||||||||||||||||||
| Deferred income taxes, net | |||||||||||||||||||
| Accrued interest receivable | |||||||||||||||||||
| Bank owned life insurance | |||||||||||||||||||
| Other assets | |||||||||||||||||||
| Total Assets | |||||||||||||||||||
| Liabilities and Stockholders' Equity | |||||||||||||||||||
| Liabilities | |||||||||||||||||||
| Deposits | |||||||||||||||||||
| Borrowings | |||||||||||||||||||
| Accrued expenses and other liabilities | |||||||||||||||||||
| Total Liabilities | |||||||||||||||||||
| Stockholders' Equity | |||||||||||||||||||
| Preferred Stock, $0.01 par value, 10,000,000 shares authorized; -0- issued and outstanding at September 30, 2025 and December 31, 2024 | |||||||||||||||||||
| Common Stock, $0.01 par value, 40,000,000 shares authorized; 2,551,780 (including 66,716 unvested restricted shares) and 2,552,115 (including 67,846 unvested restricted shares) issued and outstanding at September 30, 2025 and December 31, 2024, respectively | |||||||||||||||||||
| Additional paid-in capital | |||||||||||||||||||
| Retained earnings | |||||||||||||||||||
| Unearned ESOP shares, 177,744 shares at September 30, 2025 and December 31, 2024 | |||||||||||||||||||
| Accumulated other comprehensive loss | |||||||||||||||||||
| Total Stockholders' Equity | |||||||||||||||||||
| Total Liabilities and Stockholders' Equity | |||||||||||||||||||
Loading...
